CLOU vs IBB
Global X Cloud Computing ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.68% for CLOU.
- • IBB pays a higher dividend yield (0.16%).
Side-by-side metrics
| Metric | CLOU | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.68% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $399M | $11.50B |
YTD return | 15.61% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.04 | 0.60 |
P/E ratio | 29.48 | 25.48 |
Last price | $26.61 | $217.75 |
Inception | — | — |
Issuer | Global X | iShares |
CLOU top holdings
| SNOW | Snowflake Inc Ordinary Shares | 6.57% |
| PAYC | Paycom Software Inc | 6.11% |
| ZS | Zscaler Inc | 5.33% |
| DDOG | Datadog Inc Class A | 5.21% |
| QLYS | Qualys Inc | 4.94% |
| WDAY | Workday Inc Class A | 4.73% |
| TWLO | Twilio Inc Class A | 4.06% |
| NET | Cloudflare Inc | 4.01% |
| SHOP | Shopify Inc Registered Shs -A- Subord Vtg | 3.81% |
| CRM | Salesforce Inc | 3.81% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About CLOU
CLOU (Global X Cloud Computing ETF) is Cloud computing infrastructure and platform companies. Managed by Global X, the fund carries $399M in assets under management, an expense ratio of 0.68%. Its largest holding is Snowflake Inc Ordinary Shares (SNOW), which represents 6.6% of the portfolio. Real Estate is the fund's largest sector exposure at 2.6%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.